Jump to main content
Jump to site search

Issue 33, 2016
Previous Article Next Article

Dual-drug loaded nanoformulation with a galactosamine homing moiety for liver-targeted anticancer therapy

Author affiliations

Abstract

Drug resistance and unfavorable pharmacokinetics are the major obstacles for conventional anticancer drugs. A combination of different anticancer drugs into one formulation is a common strategy to alleviate the side effects of individual drugs in clinical practice. Platinum anticancer drugs are the typical defective therapeutic agents for cancer chemotherapy and have poor selectivity for tumor cells. In this study, a nanosystem composed of poly(lactic-co-glycolic acid) (PLGA), PtIV prodrug (PPD) and α-tocopheryl succinate (α-TOS) was designed to overcome these defects. The PtIV prodrug, c,c,t-[Pt(NH3)2Cl2(O2CC(CH3)3)2], was prepared by the reaction of oxoplatin with trimethylacetic anhydride and its structure was characterized by X-ray crystallography. The PPD and α-TOS self-assembled with PLGA, forming a dual-drug loaded nanoparticle (DDNP). The surface of the DDNP was decorated with galactosamine (G), giving rise to a G-DDNP that can actively target the liver cancer cells through the overexpressed asialoglycoprotein receptors. The DDNPs and G-DDNPs were characterized by SEM, TEM, and DLS. They are spherical in shape with required polydispersity and suitable mean size (ca. 150 nm). The in vitro cytotoxicity of DDNPs and G-DDNPs was tested against the human SMMC-7721 liver cancer cell line. G-DDNPs are more potent than the corresponding free drugs and untargeted DDNP, showing that some synergistic and tumor-specific effects are achieved by this strategy. The results demonstrate that dual-drug loaded nanoformulations with tumor-targeting function could be effective anticancer agents for conquering the shortcomings related to single-drug chemotherapy.

Graphical abstract: Dual-drug loaded nanoformulation with a galactosamine homing moiety for liver-targeted anticancer therapy

Back to tab navigation

Supplementary files

Article information


Submitted
14 Apr 2016
Accepted
09 Jun 2016
First published
09 Jun 2016

Dalton Trans., 2016,45, 13169-13178
Article type
Paper

Dual-drug loaded nanoformulation with a galactosamine homing moiety for liver-targeted anticancer therapy

N. Muhammad, X. Wang, K. Wang, C. Zhu, Z. Zhu, Y. Jiao and Z. Guo, Dalton Trans., 2016, 45, 13169 DOI: 10.1039/C6DT01434H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.


Social activity

Search articles by author

Spotlight

Advertisements